Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: The OPTRICON study

Alimentary Pharmacology and Therapeutics

Volumn 41, Issue 6, 2015, Pages 581-589

  Molina Infante, J ^a   Lucendo, A J ^b   Angueira, T ^b   Rodriguez Tellez, M ^c   Perez Aisa, A ^d   Balboa, A ^e   Barrio, J ^f   Martin Noguerol, E ^g   Gomez Rodriguez, B J ^h   Botargues Bote, J M ⁱ   Gomez Camarero, J ^j   Huerta, A ^k   Modolell, I ^l   Arino I ^m   Herranz Bachiller, M T ⁿ   Bermejo, F ⁿ   McNicholl, A G ^o   O'Morain, C ^p   Gisbert, J P ^q,r,s  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

^b Hospital General   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d Agencia Sanitaria Costa del Sol   (Spain)

^e CENTRO MÉDICO TEKNON   (Spain)

^f HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

^g HOSPITAL SEVERO OCHOA   (Spain)

^h HOSPITAL UNIVERSITARI SAGRAT COR   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^k Hospital Universitario HM Sanchinarro   (Spain)

^l Brain   (Spain)

^m INSTITUTO DE SALUD CARLOS III   (Spain)

ⁿ HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^o HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^p ADELAIDE AND MEATH HOSPITAL   (Ireland)

^q Hospiten Estepona   (Spain)

^r HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^s HOSPITAL VIRGEN DEL PUERTO   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ADULT; AGED; APHTHOUS STOMATITIS; ARTICLE; BACTERIAL CLEARANCE; COMBINATION CHEMOTHERAPY; COMPARATIVE STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; METALLIC TASTE; NAUSEA; NONHUMAN; OROPHARYNX CANDIDIASIS; PATIENT COMPLIANCE; PROSPECTIVE STUDY; RASH; SPAIN; TREATMENT DURATION; VAGINA CANDIDIASIS; VOMITING; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECTS; HELICOBACTER INFECTIONS; ISOLATION AND PURIFICATION; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG THERAPY, COMBINATION; ESOMEPRAZOLE; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MEDICATION ADHERENCE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84922923734     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13069     Document Type: Article

References (41)

1. Chey WD, Wong BC,. American College of Gastroenterology Guideline on the management of Helicobacter Pylori infection. Am J Gastroenterol 2007; 102: 1808-25.
2. Malfertheiner P, Megraud F, O'Morain C, et al,. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81.
3. Fock KM, Katelaris P, Sugano K, et al,. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-600.
4. Megraud F, Coenen S, Versporten A, et al,. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42.
5. Graham DY, Fischbach L,. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-53.
6. Graham DY, Lee YC, Wu MS,. Rational Helicobacter pylori therapy: evidence based medicine rather than medicine based evidence. Clin Gastroenterol Hepatol 2014; 12: 177-86.
7. Malfertheiner P, Megraud F, O'Morain CA, et al,. Management of Helicobacter pylori infection-the Maastricht IV/ Florence Consensus Report. Gut 2012; 61: 646-64.
8. Jafri NS, Hornung CA, Howden CW,. Meta-analysis: sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-31.
9. Tong JL, Ran ZH, Shen J, Xiao SD,. Sequential therapy vs. standard triple therapies for Helicobacter pylori infection: a meta-analysis. J Clin Pharm Ther 2009; 34: 41-53.
10. Gatta L, Vakil N, Leandro G, Di Mario F, Vaira D,. Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children. Am J Gastroenterol 2009; 104: 3069-79.
11. Essa AS, Kramer JR, Graham DY, Treiber G,. Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing "concomitant therapy" versus triple therapy for Helicobacter pylori eradication. Helicobacter 2009; 14: 109-18.
12. Gisbert JP, Calvet X,. Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori. Clin Exp Gastroenterol 2012; 5: 23-34.
13. Horvath A, Dziechciarz P, Szajewska H,. Meta-analysis: sequential therapy for Helicobacter pylori eradication in children. Aliment Pharmacol Ther 2012; 36: 534-41.
14. Zullo A, Hassan C, Ridola L, De Francesco V, Vaira D,. Standard triple and sequential therapies for Helicobacter pylori eradication: an update. Eur J Intern Med 2013; 24: 16-9.
15. Kate V, Kalayarasan R, Ananthakrishnan N,. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a systematic review of recent evidence. Drugs 2013; 73: 815-24.
16. Yoon H, Lee DH, Kim N, et al,. Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults? J Gastroenterol Hepatol 2013; 28: 1801-9.
17. Kim JS, Kim BW, Ham JH, et al,. Sequential therapy for helicobacter pylori infection in Korea: systematic review and meta-analysis. Gut Liv 2013; 7: 546-51.
18. Nyssen OP, McNicholl AG, Megraud F, et al,. Meta-analysis of sequential vs. standard triple therapy for Helicobacter pylori eradication: final results of a Cochrane systematic review. Gastroenterology 2014; 146 (Suppl 1): S-393.
19. Gatta L, Vakil N, Vaira D, Scarpignato C,. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy. BMJ 2013; 347: f4587.
20. Nyssen OP, McNicholl AG, Megraud F, et al,. Meta-analysis of sequential vs. standard triple therapy for Helicobacter pylori eradication: final results of a Cochrane systematic review. Helicobacter 2014; 19 (Suppl 1): 129.
21. Cross E, Genta RM, Dumbar KB, et al,. Sequential therapy is not better at eradication of primary Helicobacter pylori infection when compared to standard triple therapy in the United States-a prospective, randomized evaluation in a United States population. Gastroenterology 2014; 1: S-399.
22. Georgopoulos S, Papastergiou V, Xirouchakis E, et al,. Evaluation of a four-drug, three-antibiotic, nonbismuth-containing "concomitant" therapy as first-line Helicobacter pylori eradication regimen in Greece. Helicobacter 2012; 17: 49-53.
23. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al,. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology 2013; 145: 121-8.
24. Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, et al,. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area. Helicobacter 2013; 18: 459-67.
25. McNicholl AG, Marin AC, Molina-Infante J, et al,. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut 2014; 63: 244-9.
26. Gisbert JP, Calvet X, Bermejo F, et al,. III Spanish consensus conference on Helicobacter pylori infection. Gastroenterol Hepatol 2013; 36: 340-74.
27. McNicholl AG, Linares PM, Nyssen OP, Calvet X, Gisbert JP,. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36: 414-25.
28. Sahara S, Sugimoto M, Uotani T, et al,. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole. Aliment Pharmacol Ther 2013; 38: 1129-37.
29. Sánchez-Delgado J, García-Iglesias P, Castro-Fernández M, et al,. High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates. Aliment Pharmacol Ther 2012; 36: 190-6.
30. Sierra F, Forero JD, Rey M, Botero ML, Cárdenas A,. Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication. Aliment Pharmacol Ther 2013; 37: 1165-71.
31. Molina-Infante J, Gisbert JP,. Update on the efficacy of triple therapy for Helicobacter pylori infection and clarithromycin resistance rates in Spain (2007-2012). Gastroenterol Hepatol 2013; 36: 375-81.
32. Liou JM, Chen CC, Chen MJ, et al,. Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet 2013; 381: 205-13.
33. Georgopoulos SD, Xirouchakis E, Mentris A,. Is there a nonbismuth quadruple therapy that can reliably overcome bacterial resistance? Gastroenterology 2013; 145: 1496-7.
34. McNicholl AG, Nyssen OP, Gisbert JP,. Sequential and Concomitant Treatments in H. pylori Eradication: a Network Meta-Analysis. Gastroenterology 2014; 146 (Suppl 1): S-393.
35. Molina-Infante J, Pazos-Pacheco C, Vinagre-Rodriguez G, et al,. Non-bismuth quadruple (concomitant) therapy: empiric and tailored efficacy vs. standard triple therapy for clarithromycin-susceptible Helicobacter pylori and vs. sequential therapy for clarithromycin-resistant strains. Helicobacter 2012; 17: 269-76.
36. Gisbert JP, Molina-Infante J, Harb Y, et al,. Non-Bismuth Quadruple (Concomitant) Therapy for Eradication of H. pylori: standard vs. Optimized (14-Day, High-Dose PPI) Regimen. Gastroenterology 2014; Suppl. 1: S-394.
37. Georgopoulos SD, Xirouchakis E, Zampeli E, et al,. A randomised study comparing 10 days concomitant and sequential treatments for the eradication of Helicobacter pylori, in a high clarithromycin resistance area. Helicobacter 2014; 19 (Suppl 1): 80.
38. Graham DY, Fischbach LA,. Letter: the ethics of using inferior regimens in H. pylori randomised trials. Aliment Pharmacol Ther 2012; 35: 852-4.
39. Gisbert JP, Calvet X,. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011; 34: 1255-68.
40. Gisbert JP,. Is culture necessary before first-line treatment for Helicobacter pylori infection? Intern Med 2011; 50: 2717.
41. Malfertheiner P, Bazzoli F, Delchier JC, et al,. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, openlabel, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-13.